Optimizing Co-Management of Patients With Upper GI Cancers (GC/GEJC/EAC) Using a Tumor Board Model

Intended Audience: Medical oncologists, surgical oncologists, gastroenterologists, pathologists, NPs, PAs, nurses, and pharmacists involved in the treatment of patients with upper GI cancers

The treatment of upper gastrointestinal (GI) malignancies requires communication between the multidisciplinary team to ensure optimal care. Join us for this on-demand video as an expert oncologist and surgeon highlight insights learned from a recent multidisciplinary tumor board-based quality improvement program, and review the latest clinical evidence and guideline recommendations for caring for patients with gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. Don't miss out on this opportunity to learn about expert strategies to improve patient care in your own practice!

• Evaluate the latest clinical data on safety and efficacy for current and emerging therapies in GC, GEJC, and EAC
• Apply current guidelines and recent clinical efficacy and safety data to guide selection and sequencing of available therapies for GC, GEJC, and EAC, including identification of eligible patients and timing of pharmacologic intervention in relation to potential surgical intervention
• Evaluate evidence-based practices for monitoring and mitigating adverse events associated with novel therapies for GC, GEJC, and EAC

PRIME Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 060815. This activity is approved for 0.5 contact hour (which includes 0.35 hour of pharmacology).

*PRIME® has identified, reviewed, and mitigated all relevant financial relationships that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity.

The following individuals have identified relevant financial relationships with ineligible companies to disclose:

• Jaffer A. Ajani, MD (Speaker)
  
  Advisory Board or Panel – Amgen, Astellas, Bristol-Myers Squibb, Daiichi, Gilead Sciences, Merck, Novartis, Zymeworks
  The relationships reported above are related to the following therapeutic area: Oncology
• Stephen R Broderick, MD, MPHS (Speaker)
  
  Advisory Board or Panel – Bristol-Myers Squibb
  Consultant – Bristol-Myers Squibb
  The relationships reported above are related to the following therapeutic area: Solid Tumor

The following individuals have no relevant financial relationships with ineligible companies to disclose:

• Joyce M Knestrick, PhD, CRNP, FAANP (Reviewer)
• Ricardo Correa, MD, EdD, FACP, FACE, FAPCR, FACMQ (Planner)
• Abimbola Farinde, PhD, PharmD (Planner)

All PRIME® staff participating in planning and content development have no relevant financial relationships with ineligible companies to disclose.